United States — Food and Drug Administration & Apple Inc.

United States — Food and Drug Administration: The United States — Food and Drug Administration cleared the EpiWatch app for marketing, providing regulatory approval that validates its safety and effectiveness. This clearance is crucial for the app's commercialization and adoption in healthcare.

Apple Inc.: The EpiWatch app operates on the Apple Inc., enhancing the device's utility and potentially increasing its market appeal to individuals with epilepsy and their caregivers. This expands the use cases for the Apple Inc. beyond general fitness and communication.

United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Revolution Medicines will seek approval from for its experimental pancreatic cancer drug, daraxonrasib.

Apple Inc.: Apple Inc. is unveiling new AI features at its annual developers conference, aiming to catch up with competitors in the AI space and potentially boost its market position.